FDA CRL - SFJ Pharmaceuticals, Inc.

SFJ Pharmaceuticals, Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA 761290). The FDA determined that the application could not be approved in its current form due to several outstanding issues. The primary concerns highlighted include deficiencies in Product Quality and Quality Microbiology. Furthermore, facility inspections identified issues, requiring satisfactory responses to FDA Form 483 observations from the manufacturing sites. The FDA emphasized that resolution of these inspection deficiencies, potentially involving re-inspection, is crucial for approval. To address these concerns, SFJ Pharmaceuticals must provide comprehensive responses to all identified deficiencies. Key required actions include resolving all product quality and microbiology issues, and ensuring the facilities provide adequate responses to inspection findings. Additionally, the company must submit a detailed safety update, incorporating new clinical and non-clinical data, and comparing it with original application data, as per 21 CFR 314.50(d)(5)(vi)(b). Resubmission of the proposed proprietary name and addressing labeling comments are also required once other issues are resolved. The company has one year to resubmit a complete response, failing which the application may be considered withdrawn. Approval is necessary before the product can be legally marketed.